| Randomisation | Group A | 7 (23.3) |
| Group B | 9 (30.0) |
| Group C | 1 (3.3) |
| Group D | 13 (43.3) |
| Demography | Age (years) | 54 ± 11 |
| Height (m) | 1.65 ± 0.07 |
| BMI (kg/m2) | 26.0 ± 4.6 |
| Diagnosis | Adjuvant | 26 (86.7) |
| Metastatic or local advanced | 4 (13.3) |
| Tumour entity | Breast Cancer | 22 (73,33) |
| Endometrial Cancer | 2 (6,7) |
| Ovarian Cancer | 2 (6.7) |
| Cervical Cancer | 4 (13,3) |
| T-categories | T1 | 10 (33.3) |
| T2 | 14 (46.7) |
| T3 | 3 (10.0) |
| T4 | 3 (10.0) |
| Nodal status | N0 | 20 (66.7) |
| N1 | 8 (26.7) |
| N2 | 1 (3.3) |
| N3 | 1 (3.3) |
| Metastasis | M0 | 27 (90.0) |
| M1 | 3 (10.0) |
| Chemotherapy regimens | Paclitaxel/Carboplatin | 7 (23.3) |
| Epirubicin/Cyclophosphamid | 22 (73.3) |
| Docetaxel/Cyclophosphamid | 1 (3.3) |
| Treatment | Adjuvant chemotherapy | 6 (20) |
| Neoadjuvant chemotherapy | 22 (73.3) |
| Palliative chemotherapy | 3 (10.0) |
| Nutritional status (NRS 2002) | 1 | 21 (70.0) |
| 2 | 8 (26.7) |
| 3 | 1 (3.3) |
| Energy requirement | Basal metabolic rate (kcal) | 1391 ± 125 |
| Physical Activity Level | 1.39 ± 0.06 |
| Active metabolic rate (kcal) | 1933 ± 178 |
| 25% of the active metabolic rate (kcal) | 484 ± 44 |
